

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|             |   |                        |
|-------------|---|------------------------|
| Applicant:  | Bamborough, et al.  | 23 October 2008        |
| Serial No.: | 10/558,790  | Group Art Unit: 1614   |
| Filed:      | 28 July 2006  | Examiner: A. Pagonakis |
| For:        | Fused Heteroaryl Derivatives for Use As p38 Kinase Inhibitors |                        |

FILING OF A SECOND INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

This paper is being filed contemporaneously with a First Information Disclosure Statement disclosing Applicant's related applications. Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



Dara L. Dinner  
Attorney for Applicants  
Registration No. 33,680

GLAXOSMITHKLINE  
Corporate Intellectual Property-UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone: (610) 270-5017  
Facsimile: (610) 270-5090